A Microdose Evaluation Study of ABY-029 in Head and Neck Oncology Surgery
Status:
Completed
Trial end date:
2020-12-18
Target enrollment:
Participant gender:
Summary
The primary study objective is to determine if microdoses of ABY-029 (up to 6X) lead to
detectable signals (defined as signal-to-noise ratio, SNR ≥10, with wide-field iFI) in
sampled tissues with an EGFR (epidermal growth factor receptor) pathology score ≥ 1 based on
histological staining.
The secondary study objective is to assess ex vivo the specificity of tumor binding in
resected specimens by measuring the corresponding molecular uptake and concentrations using
histopathology.